glp-1 drug companies Comparing Ozempic, Wegovy and Other Drugs 2025’s Breakthrough GLP-1 Obesity Treatments:

Diabetes 49(4), 611617

Prior reports have also cited cost to be a barrier to use for a large portion of patients, with monthly costs up to $1349 before insurance, rebates, or other discounts ( 2 , 12 )

However, evidence in PsA remains limited, with most studies constrained by small sample sizes and short follow-up periods

Available from: ideas/obesity-drugs-food-industry 5 Schafer, 2023

A meta-analysis of clinical studies indicated that treatment with GLP-1RAs of obese patients with T2MD did not increase the risk of breast tumors, nor did it increase the risk of acute pancreatitis, pancreatic cancer, and overall tumor neoplasia (207209)